Abraham Ceesay, Chief Executive Officer at Rapport Therapeutics, Inc. (RAPP), sold 21,832 shares at $24.91 ($550K) on 2025-11-17, disclosed to the SEC on 2025-11-18.
Scheduled sale ($550k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.91 | 2,242 | $56K | 10.2% |
| 2 | $24.91 | 2,242 | $56K | 10.2% |
| 3 | $24.92 | 2,777 | $69K | 12.6% |
| 4 | $24.92 | 2,777 | $69K | 12.6% |
| 5 | $25.43 | 3,056 | $78K | 14.1% |
| 6 | $25.43 | 3,056 |
| $78K |
| 14.1% |
| 7 | $25.44 | 2,841 | $72K | 13.1% |
| 8 | $25.44 | 2,841 | $72K | 13.1% |
| Total | $25.20 avg | 21,832 | $550K | 100% |
| Filing → |
| RAPP | SELL | 2026-08-26 | $938K | — | Filing → |
| RAPP | SELL | 2026-08-12 | $2.4M | — | Filing → |
| RAPP | SELL | 2026-07-29 | $93K | — | Filing → |